Homepage Top Section1

Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95

This marks Nefecon as the first FDA-approved treatment for IgAN. Nefecon is an oral, delayed-release formulation of budesonide, a corticosteroid with potent anti-inflammatory properties. The enteric-coated capsule approval

ATX101 is designed for sustained, localised pain relief post total knee arthroplasty surgery. Under the agreement, Allay will receive an upfront payment and equity investment. It is also

Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,

The first-in-class C5 complement inhibitor, Soliris has been indicated for anti-acetylcholine receptor antibody-positive children and adolescents aged six to 17 years. It is claimed to be the first

The letter is based on a continuing assessment of inspection data at a third-party filler. No issues linked to aflibercept’s clinical safety or efficacy, design of the clinical

Ensitrelvir is a COVID antiviral presently approved in Japan and being analysed in clinical trials outside of the country. The sublicence agreements were inked with three generic manufacturing

Under the deal terms, Lilly will begin a tender offer to purchase all outstanding shares of DICE for an acquisition price of $48 per share in cash, which translates to a total

Initially, the companies signed a manufacturing agreement in March last year for a Pfizer product. As per the new agreement terms, Samsung Biologics will provide Pfizer with more